Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Elekta AB ( ($SE:EKTA.B) ) has issued an announcement.
Elekta’s Nomination Committee has proposed the reelection of several board members and the election of Jan De Witte as a new director for the upcoming term. Jan De Witte brings extensive leadership experience from the global technology and life science industries, which could enhance Elekta’s strategic direction and industry positioning.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care. The company collaborates with customers to develop sustainable, outcome-driven, and cost-efficient solutions to meet patient needs and improve lives. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 1,426,961
Current Market Cap: SEK18.47B
See more data about EKTA.B stock on TipRanks’ Stock Analysis page.